Mesenchymal stem cells therapy enhances the efficacy of pregabalin and prevents its motor impairment in paclitaxel-induced neuropathy in rats: Role of Notch1 receptor and JAK/STAT signaling pathway

Al-Massri, Khaled F.; Ahmed, Lamiaa A.; El‐Abhar, Hanan S.

doi:10.1016/j.bbr.2018.12.013

Cited by 38 publications

(45 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The antioxidant properties of stem cells were described in previous studies in vitro (Whone, Kemp, Sun, Wilkins, & Scolding, ; Yalvaç et al, ) and in vivo (Li, Li, Liu, Tang, & Wei, ; Lin et al, ). In line with these data, MSCs were found to influence the spinal redox context and activate the antioxidant defense system in models of traumatic spinal cord injury (Lin et al, ) and amyotrophic lateral sclerosis (Uccelli et al, ), as well as PTX‐induced peripheral neuropathy through restoring the total antioxidant capacity in the sciatic nerve (Al‐Massri et al, ).…”

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 74%

“…Despite the scarcity of data about the role of MSCs in CIPN, its positive potential against CIPN was proven in a previous study confirming that MSCs protected sensory neurons, but not cortical neurons, from the chemotherapy‐induced neurotoxicity (Monfrini, Donzelli, Rodriguez‐Menendez, & Scuteri, ). Again, our recent study (Figure ) also showed that BM‐MSCs improved paclitaxel (PTX)–induced peripheral neuropathy in rats through inhibiting neuronal oxidative stress, inflammation, and apoptosis as well as maintaining nerve function and promoting axonal regeneration (Al‐Massri, Ahmed, & El‐Abhar, ). The impact of MSCs on other diseases associated with peripheral neuropathy has been addressed; one experimental study concluded that MSCs transplantation alleviated the symptoms of neuropathic pain and resulted in subsequent motor recovery after spinal cord injury in rats (Yousefifard et al, ).…”

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 84%

“…The modulatory action of MSCs on cytokine expression in peripheral tissues was previously demonstrated (Omi et al, ; Waterman et al, ). For example, treatment with MSCs reduced the levels of inflammatory markers such as NF‐κB p65, IL‐1β, TNF‐α, and IL‐6 in the sciatic nerve and spinal cord in experimental models of neuropathic pain (Al‐Massri et al, ; Gama et al, ). In addition, MSCs administration enhanced the levels of the anti‐inflammatory cytokines such as IL‐10 and TGF‐β in the spinal cord of neuropathic mice (Chen et al, ; Echeverry, Shi, Haw, Liu, & Zhang, Z.‐w.,, & Zhang, J., ; Milligan, Penzkover, Soderquist, & Mahoney, ).…”

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 99%

“…These results support the fact that this cue is associated with neuropathic pain regulation (Li, Yan, Yu, & Duan, ). Therefore, the decreased content of IL‐6 by using MSCs could abate in turn the protein expressions of its downstream molecule p ‐JAK2 and consequently p ‐STAT3 (Al‐Massri et al, ).…”

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 99%

“…Furthermore, blocking CX3CL1 was found to decrease p38‐MAPK activity and thus blocking the neuronal apoptosis and development of mechanical allodynia induced by PTX (Huang et al, ). Therefore, the anti‐inflammatory capacity of BM‐MSCs entails the inactivation of p38‐MAPK, beside its downstreams (NF‐κB, TNF‐α, and IL‐6) (Al‐Massri et al, ).…”

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 99%

See 4 more Smart Citations

Mesenchymal stem cells in chemotherapy‐induced peripheral neuropathy: A new challenging approach that requires further investigations

Al-Massri

Ahmed

El‐Abhar

2019

J Tissue Eng Regen Med

Self Cite

View full text Add to dashboard Cite

Chemotherapeutic drugs may disrupt the nervous system and cause chemotherapyinduced peripheral neuropathy (CIPN) as side effects. There are no completely successful medications for the prevention or treatment of CIPN. Many drugs such as tricyclic antidepressants and anticonvulsants have been used for symptomatic treatment of CIPN. Unfortunately, these drugs often give only partial relief or have dose-limiting side effects. Thus, the treatment of CIPN becomes a challenge because of failure to regenerate and repair the injured neurons. Mesenchymal stem cell (MSC) therapy is a new attractive approach for CIPN. Evidence has demonstrated that MSCs play important roles in reducing oxidative stress, neuroinflammation, and apoptosis, as well as mediating axon regeneration after nerve damage in several experimental studies and some clinical trials. We will briefly review the pathogenesis of CIPN, traditional therapies used and their drawbacks as well as therapeutic effects of MSCs, their related mechanisms, future challenges for their clinical application, and the additional benefit of their combination with pharmacological agents. MSCs-based therapies may provide a new therapeutic strategy for patients suffering from CIPN where further investigations are required for studying their exact mechanisms. Combined therapy with pharmacological agents can provide another promising option for enhancing MSC therapy success while limiting its adverse effects.

show abstract

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 74%

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 84%

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 99%

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 99%

Section: Mscs Therapy In Cipn and Peripheral Neuropathymentioning

confidence: 99%

See 3 more Smart Citations

Mesenchymal stem cells in chemotherapy‐induced peripheral neuropathy: A new challenging approach that requires further investigations

Al-Massri

Ahmed

El‐Abhar

2019

J Tissue Eng Regen Med

Self Cite

View full text Add to dashboard Cite

show abstract

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Hetta,

Elsaghir,

Sijercic

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundDiabetes has evolved into a worldwide public health issue. One of the most serious complications of diabetes is diabetic foot ulcer (DFU), which frequently creates a significant financial strain on patients and lowers their quality of life. Up until now, there has been no curative therapy for DFU, only symptomatic relief or an interruption in the disease's progression. Recent studies have focused attention on mesenchymal stem cells (MSCs), which provide innovative and potential treatment candidates for several illnesses as they can differentiate into various cell types. They are mostly extracted from the placenta, adipose tissue, umbilical cord (UC), and bone marrow (BM). Regardless of their origin, they show comparable features and small deviations. Our goal is to investigate MSCs' therapeutic effects, application obstacles, and patient benefit strategies for DFU therapy.MethodologyA comprehensive search was conducted using specific keywords relating to DFU, MSCs, and connected topics in the databases of Medline, Scopus, Web of Science, and PubMed. The main focus of the selection criteria was on English‐language literature that explored the relationship between DFU, MSCs, and related factors.Results and DiscussionNumerous studies are being conducted and have demonstrated that MSCs can induce re‐epithelialization and angiogenesis, decrease inflammation, contribute to immunological modulation, and subsequently promote DFU healing, making them a promising approach to treating DFU. This review article provides a general snapshot of DFU (including clinical presentation, risk factors and etiopathogenesis, and conventional treatment) and discusses the clinical progress of MSCs in the management of DFU, taking into consideration the side effects and challenges during the application of MSCs and how to overcome these challenges to achieve maximum benefits.ConclusionThe incorporation of MSCs in the management of DFU highlights their potential as a feasible therapeutic strategy. Establishing a comprehensive understanding of the complex relationship between DFU pathophysiology, MSC therapies, and related obstacles is essential for optimizing therapy outcomes and maximizing patient benefits.

show abstract

Bone marrow‐derived mesenchymal stem cells alleviate paclitaxel‐induced mechanical allodynia in rats

Sezer

Yay

Sarica

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Anticancer drug paclitaxel (PTX) frequently causes painful peripheral neuropathy; however, no medication has been shown to be effective in the treatment of this debilitating side effect. We aimed to investigate the efficacy of two different doses of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) on PTX-induced mechanical allodynia and spinal cytokine levels and their localization to target tissues such as the spinal cord and sciatic nerve. After the development of mechanical allodynia with repeated PTX administration, two different doses of rat BM-MSCs, low or high (1 × 10 6 -5 × 10 6 ), were transplanted into rats and the evaluation continued for 30 days. Interleukin (IL)-1β, tumor necrosis factor (TNF)-α, and IL-10 levels in spinal cord samples of animals were analyzed by enzyme-linked immunosorbent assay. PTX-induced mechanical allodynia was relieved significantly 15 days after the transplantation of high-dose of BM-MSCs. Both MSCs doses were effective in alleviating allodynia, but the onset of effect was earlier with the high dose. High-dose of BM-MSCs significantly decreased spinal IL-1β and TNF-α levels compared to the PTX group. Fluorescent dye-labeled BM-MSCs were observed much more frequently in the sciatic nerve and spinal cord samples of the high-dose BM-MSCs transplanted group than in the low-dose group animals. In conclusion, we found that the antiallodynic effects of BM-MSCs appeared earlier when high-dose of cells were administered. We think that other mechanisms may play a role in the effects of MSCs, besides localization to damaged tissues and reducing spinal inflammatory cytokine levels. We show that BM-MSCs can be a novel approach in PTX-induced mechanical allodynia.

show abstract

Mesenchymal stem cells therapy enhances the efficacy of pregabalin and prevents its motor impairment in paclitaxel-induced neuropathy in rats: Role of Notch1 receptor and JAK/STAT signaling pathway

Cited by 38 publications

References 62 publications

Mesenchymal stem cells in chemotherapy‐induced peripheral neuropathy: A new challenging approach that requires further investigations

Mesenchymal stem cells in chemotherapy‐induced peripheral neuropathy: A new challenging approach that requires further investigations

Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review

Bone marrow‐derived mesenchymal stem cells alleviate paclitaxel‐induced mechanical allodynia in rats

Contact Info

Product

Resources

About